Cost Effectiveness of Dapagliflozin Added to Standard of Care for the Management of Diabetic Nephropathy in the USA
The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Background Angiotensin-converting enzyme inhibitors have been used as the standard of care for the treatment of diabetic nephropathy. Recently, dapagliflozin has been shown to reduce diabetic nephropathy when added to the standard of care.Objective The objective of this study was to determine the cost effectiveness of dapagliflozin added to the standard of care in diabetic nephropathy in the United States of America (USA).Methods A Markov model was developed to determine the cost-effectiveness outcomes from the Medicare/Medicaid health coverage perspective. Model inputs were derived from the literature. The primary outcomes were total costs, quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio. Deterministic and probabilistic sensitivity analyses were performed to determine the robustness of our results. A willingness-to-pay threshold of $100,000 per QALY was applied, which is based on previous studies.Results Dapagliflozin yielded a lifetime QALY of 2.8. The discounted QALY associated with the standard of care was 2.6. The standard of care was the less costly treatment with a lifetime cost of $106,150.25 as compared with dapagliflozin, which costs $110,689.25. Dapagliflozin demonstrated an incremental cost-effectiveness ratio of $21,141.51 per additional QALY. The most influential parameters of the incremental cost-effectiveness ratio were the adverse drug reaction-related cost of the standard of care and dapagliflozin, the acquisition cost, and the adverse drug reaction-related cost of dapagliflozin. The effects and costs of the interventions were consistent between base-case analyses and the probabilistic model (incremental cost-effectiveness ratio: $19,023.35 [$13,637.8-$27,483.1]).Conclusions Dapagliflozin added to the standard of care was cost effective relative to the standard of care alone in the USA for patients with diabetic nephropathy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Avoiding or delaying costly kidney replacement therapy may make it cost-effective to implement the new therapies, [41][42][43] but more data are needed to support this possibility.”
Citations
Cites
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 1×
“Dapagliflozin is one of the SGLT2i that reduces the risk of kidney disease progression [12].”
BackgroundDapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618 · cited 1×
“Our finding is supported with another study in which dapagliflozin improved renal function and reduced the progression of kidney disease in patients with or without diabetes, which may result in better health outcome [76].”
ResultWolfe, R. A., Ashby, V. B., Milford, E. L., Ojo, A. O., Ettenger, R. E., Agodoa, L. Y. C., Held, P. J., & Port, F. K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912023412303 · Cited by 5,371
Sanders, G. D., Neumann, P. J., Basu, A., Brock, D. W., Feeny, D., Krahn, M., Kuntz, K. M., Meltzer, D. O., Owens, D. K., Prosser, L. A., et al. (2016) · JAMA · doi:10.1001/jama.2016.12195 · Cited by 3,069 · cited 12×
“Captopril is the only USA Food and Drug Administration-approved angiotensinconverting enzyme inhibitor to reduce proteinuria and to slow DN [8, 9].”
MethodInfluentialDiabetic nephropathy: diagnosis, prevention, and treatment
Gross, J. L., de Azevedo, M. J., Silveiro, S. P., Canani, L. H., Caramori, M. L., & Zelmanovitz, T. (2005) · Diabetes Care · doi:10.2337/diacare.28.1.164 · Cited by 1,839
Nathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832
Adler, A. I., Stevens, R. J., Manley, S. E., Bilous, R. W., Cull, C. A., Holman, R. R., & UKPDS Group (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00712.x · Cited by 1,816
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399 · cited 1×
“More recently, sodium-glucose cotransporter inhibitors (SGLT2i) were shown to reduce chronic kidney disease progression when added to the SoC [10].”
BackgroundUS Renal Data System 2020 annual data report: epidemiology of kidney disease in the United States
Johansen, K. L., Chertow, G. M., Foley, R. N., Gilbertson, D. T., Herzog, C. A., Ishani, A., Israni, A. K., Ku, E., Kurella Tamura, M., Li, S., et al. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.01.002 · Cited by 724 · cited 1×
“The probabilities of patients undergoing dialysis and a transplant were sourced from the 2020 US renal data system annual report [23].”
Rosenstock, J., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-1380 · Cited by 664 · cited 1×
“use of SGLT2i imposes a higher risk of DKA in patients with precipitating factors due to glycosuria [78].”
Background
Research works printed but not linked: 1
- Bergenheim K, Williams SA, Bergeson JG, Stern L, Sriprasert M. US cost-effectiveness of saxagliptin in type 2 diabetes mellitus. Am J Pharm Benefits. 2012;4(1):20–8.
Cited by
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.013 · Cited by 274
Navaneethan, S. D., Zoungas, S., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Liew, A., Michos, E. D., Olowu, W. A., Sadusky, T., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m22-2904 · Cited by 248
Yeo, S. C., Wang, H., Ang, G. Y., Lim, C. K., & Ooi, X. Y. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad137 · Cited by 91
Li, H., Dong, A., Li, N., Ma, Y., Zhang, S., Deng, Y., Chen, S., & Zhang, M. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s395512 · Cited by 30
“In addition, a recent study has shown that dapagliflozin increases the economic burden of kidney disease treatment in the United States.(9) For these reasons, there is an urgent need to find cost-effective ways to delay the progression of DKD.”
BackgroundRossing, P. R., Caramori, M. L., Chan, J. C. N., & Al., E. (2023) · KIDNEYS · doi:10.22141/2307-1257.11.4.2022.386 · Cited by 10
Metadata
- Authors
- Abegaz, T. M., Diaby, V., Sherbeny, F., & Ali, A. A.
- Affiliations
- Florida Agricultural and Mechanical University (US)
- Corresponding author
- Ali, Askal Ayalew
- Venue
- Clinical Drug Investigation
- Published
- 2022-05-25
- Volume
- 42
- Issue
- 6
- Pages
- 501-511
- ISSN
- 0114-2402 (ISSN-L)
- 1173-2563
- 1179-1918
- OpenAlex
- W4281552441
- Cited by
- 15
- References
- 67
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 1 · 2023: 5 · 2022: 1
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Clinical Drug Investigation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- dapagliflozin, diabetic nephropathy, cost-effectiveness, SGLT2 inhibitors, ACE inhibitors, quality-adjusted life years, Medicare and Medicaid, adverse drug reactions, treatment costs
- MeSH terms
- Aged, Benzhydryl Compounds, Cost-Benefit Analysis, Diabetes Mellitus, Diabetic Nephropathies, Glucosides, Medicare, Humans, United States, Quality-Adjusted Life Years, Standard of Care, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost Effectiveness of Dapagliflozin Added to Standard of Care for the Management of Diabetic Nephropathy in the USA. https://app.cochat.ai/papers/10.1007/s40261-022-01160-8
- The paper
- Abegaz, T. M., Diaby, V., Sherbeny, F., & Ali, A. A. (2022). Cost Effectiveness of Dapagliflozin Added to Standard of Care for the Management of Diabetic Nephropathy in the USA. Clinical Drug Investigation. https://doi.org/10.1007/s40261-022-01160-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.